Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals, a biotechnology company, has announced that Merck & Co has extended its research collaboration with Idera for an additional year.
Subscribe to our email newsletter
Idera and Merck have previously entered into an exclusive license and research collaboration agreement to research, develop and commercialize vaccine products containing the company’s investigational agonist compounds targeting toll-like receptors (TLR) 7, 8, and 9 in the fields of oncology, infectious diseases and Alzheimer’s disease.
As part of the agreement, the two companies engaged in a two-year research collaboration to generate novel agonists targeting TLR7 and TLR8 incorporating both Merck and Idera chemistry for use in the licensed fields.
Sudhir Agrawal, CEO of Idera, said: “Our two-year research collaboration with Merck scientists has been very productive and has created several novel agonists of TLR7 and TLR8 for potential use in vaccine products. We are looking forward to a productive third year of the collaboration to fully capitalize on the accomplishments from the first two years.”